Naba Alsaha Medical Reports SAR 15.23M Net Profit in the Six Months 2026
NABA ALSAHA 9546.SA | 0.00 |
On 2026-08-26 08:14:39 (Saudi Time), Naba Alsaha Medical Services Co. announced its Interim financial results for the six months ended on June 30, 2026.
| Element List | Current Period | Similar period for previous year | %Change | ||
|---|---|---|---|---|---|
| Sales/Revenue | 102,425,761 | 98,092,127 | 4.417 | ||
| Net Profit (Loss) Attributable to Shareholders of the Issuer | 15,226,388 | 14,208,940 | 7.16 | ||
| Total Shareholders Equity (after Deducting Minority Equity) | 238,084,949 | 210,720,749 | 12.986 | ||
| Profit (Loss) per Share | 0.73 | 0.68 | |||
| All figures are in (Actual) Saudi Arabia, Riyals | |||||
| Element List | Amount | Percentage of the capital (%) | |
|---|---|---|---|
| Profit (Losses) Resulting From The Change In Investment Propertie’s Fair Value | - | - | |
| All figures are in (Actual) Saudi Arabia, Riyals | |||
| Element List | Explanation |
|---|---|
| The reason of the increase (decrease) in the sales/ revenues during the current period compared to the same period of the last year is | The company's revenues increased by approximately SAR 4,333,634—representing a 4.4% rise—during the first half of 2026 compared to the same period of the previous year; this is attributed to an increase in patient numbers across outpatient clinics, inpatient departments, and ancillary medical services. |
| The reason of the increase (decrease) in the net profit during the current period compared to the same period of the last year is | Net profit reached SAR 15,226,388, compared to SAR 14,208,940 for the same period of the previous year—an increase of SAR 1,017,448 (7.16%). This rise is primarily attributed to revenue growth driven by an increase in the number of patients and pharmacy sales, alongside improved operational efficiency and the favorable ratio of revenue growth to expenses, which contributed to higher profit margins and net profit. |
| Statement of the type of external auditor's report | Unmodified conclusion |
| Reclassification of Comparison Items | Not Applicable |
| Additional Information | On June 4, 2026, the company increased its capital by SAR 105,000,000 through the issuance of bonus shares. Consequently, earnings per share for both the current and prior periods were adjusted retrospectively to reflect the impact of the aforementioned bonus share issuance, in accordance with the requirements of International Accounting Standard (IAS) 33. |
Year-on-Year Performance Drivers
Sales/Revenue increased 4.417% YoY to SAR 102.43 million (from SAR 98.09 million), driven by a higher volume of patients across outpatient clinics, inpatient departments, and ancillary medical services. Net profit attributable to shareholders rose 7.16% YoY to SAR 15.23 million (from SAR 14.21 million), primarily due to revenue growth from increased patient numbers and pharmacy sales, combined with improved operational efficiency and a favorable ratio of revenue growth relative to expenses, which expanded profit margins.
Other Items
The external auditor issued an unmodified conclusion for the period. Total shareholders' equity (after deducting minority equity) stood at SAR 238,084,949, compared to SAR 210,720,749 for the same period of the previous year, representing a 12.986% increase. Earnings per share were SAR 0.73 for the current period, up from SAR 0.68 in the prior comparable period. Additionally, on June 4, 2026, the company increased its capital by SAR 105,000,000 through the issuance of bonus shares; as a result, earnings per share for both the current and prior periods were adjusted retrospectively to reflect the impact of this bonus share issuance, in accordance with the requirements of International Accounting Standard (IAS) 33. No material risks, going concern uncertainties, or accumulated losses were reported.
Original announcement:
https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anId=97796&anCat=1&cs=9546&locale=arImportant Notice: The announcement information and market data in this report are sourced directly from the Saudi Exchange (Tadawul). This summary is generated by Sahm’s proprietary AI model for informational purposes only. While we strive for accuracy, it should not be construed as financial advice or an investment recommendation.